A- A A+

The Emergence of "Coachella" Heroin in the Midwest.

Sethi R, Luvisi J, Ahonen K, Irwin T.

Prim Care Companion CNS Disord. 2019 Jul 18;21(4). pii: 18l02394. doi: 10.4088/PCC.18l02394.


Novel synthetic opioids - toxicological aspects and analysis.

Tabarra I, Soares S, Rosado T, Gonçalves J, Luís Â, Malaca S, Barroso M, Keller T, Restolho J, Gallardo E.

Forensic Sci Res. 2019 Jul 3;4(2):111-140. doi: 10.1080/20961790.2019.1588933. 


A chemically contiguous hapten approach for a heroin-fentanyl vaccine.

Natori Y, Hwang CS, Lin L, Smith LC, Zhou B, Janda KD.

Beilstein J Org Chem. 2019 May 3;15:1020-1031. doi: 10.3762/bjoc.15.100.


Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids.

Olson KM, Duron DI, Womer D, Fell R, Streicher JM (2019) 

PLoS ONE 14(6): e0217371. doi.org/10.1371/journal.pone.0217371


Australien. Weekly Dose: Krokodil, the Russian ‘flesh-eating’ drug, makes a rare appearance in Australia

A young man recently turned up at a rural drug and alcohol service in New South Wales seeking help because of an infection in his arm. He said he had injected the drug Krokodil, which had not previously been reported in Australia. (The Conversation, Australien, 19.06.2019)


Tapentadol use among people who regularly inject drugs in Australia

Sutherland,R., Memedovic,S., Degenhardt,L., Farrell,M.,& Peacock,A. (2019).


Tapentadol is a centrally acting opioid analgesic registered for use in Australia to treat moderate to severe pain. A recent review has suggested a lack of data regarding ‘abuse, dependence, diversion, or recreational use’ of tapentadol. This paper addresses this research gap by examining patterns of tapentadol use among a sentinel sample of people who regularly inject drugs in Australia.


Rate of Fentanyl Positivity Among Urine Drug Test Results Positive for Cocaine or Methamphetamine.

LaRue L, Twillman RK, Dawson E, et al. 

JAMA Netw Open.2019;2(4):e192851. doi:10.1001/jamanetworkopen.2019.2851


A Promising Alternative to Opioid Pain Medications. 

NIDA. (2019, February 12). 


Chronic use of tramadol after acute pain episode: cohort study 

Thiels Cornelius A, Habermann Elizabeth B, Hooten W Michael, Jeffery Molly M. 

BMJ 2019; 365 :l1849 


US-Studie sieht Abhängigkeitspotenzial bei Tramadol

Rochester – (...) Die Autoren einer Studie im Britischen Ärzteblatt(BMJ2019; 365: l1849) vermuten (..), dass das Abhängigkeitspotenzial von Tramadol unterschätzt wird. (aerzteblatt.de, 15.05.2019)


Opioids in the immune system: from experimental studies to clinical practice.

Moyano J, Aguirre L.

Rev Assoc Med Bras (1992). 2019 Feb;65(2):262-269. doi: 10.1590/1806-9282.65.2.262. Review.


Metabolic Pathways and Potencies of New Fentanyl Analogs.

Wilde M, Pichini S, Pacifici R, Tagliabracci A, Busardò FP, Auwärter V, Solimini R.

Front Pharmacol. 2019 Apr 5;10:238. doi: 10.3389/fphar.2019.00238. 


UK. Opioid painkillers 'must carry prominent warnings'

All opioid medicines in the UK will carry prominent warnings on their labels saying they can cause addiction, the health secretary has announced. (BBC, 28.04.2019)


Neurobiologie der Opioidabhängigkeit

Scherbaum N, Bonnet U.

Anaesthesist. 2019 Mar;68(3):179-190. doi: 10.1007/s00101-019-0557-3. German. 



Understanding the molecular basis of agonist/antagonist mechanism of human mu opioid receptor through gaussian accelerated molecular dynamics method.

Wang YT, Chan YH.

Sci Rep. 2017 Aug 10;7(1):7828. doi: 10.1038/s41598-017-08224-2.


Suppression of Human Natural Killer Cells by Different Classes of Opioids.

Maher DP, Walia D, Heller NM.

Anesth Analg. 2019 Feb 18. doi: 10.1213/ANE.0000000000004058.



Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids

Ning-Sheng Cai, … , Annabelle M. Belcher, Sergi Ferre 

J Clin Invest. 2019. Published March 26, 2019, doi.org/10.1172/JCI126912. 


NIDA. Opioids without the risk of addiction?

Scientists are working to develop medicines that have the pain-relieving effects of opioids without the high risk of misuse and addiction. Since misuse is linked to the euphoric effects of the drug, investigators led by scientists at NIDA’s intramural labs are studying methadone, a drug used to manage opioid addiction that does not have euphoric effects as strong as many other opioids. (NIDA, USA, 26.03.2019)


Die pharmakologische Visitenkarte des vierten Opioid-Rezeptors

Pharmakologen aus Jena, Toulouse, St. Louis und Boca Raton sowie Montreal, Seattle und Mountain View konnten das molekulare Verhalten des Nociceptin-Rezeptors sowohl in der Zelle als auch im Organismus detailliert aufklären. Ihre jetzt in Science Signaling veröffentlichte Untersuchung des vierten Opioid-Rezeptors ist eine zentrale Vorarbeit für die Entwicklung und klinische Prüfung neuer Schmerzmittel. (Universitätsklinikum Jena, 26.03.2019)


UNODC. Global SMART Update 2019, Vol. 21 (The non-medical Use of Opioids)

The Global SMART Update is designed to provide regular brief reports on emerging patterns and trends of the global synthetic drug situation. 

The current issue provides insight into the non-medical use of opioids, which presents a significant concern for public health, safety and law enforcement authorities worldwide. In the past years, the non-medical use of potent opioids such as fentanyl and its analogues have been reported mainly from North America, as well as from Asia, Europe and Oceania. Often sold as heroin or prescription medicines, these substances have contributed to the unprecedented number of recent opioid overdose deaths. The non-medical use of tramadol, an opioid analgesic, continues to increase in parts of Africa and the Middle East with reported adverse health effects. The rapidly emerging crisis which has resulted in significant harm to human health and welfare, including fatalities, calls for a coordinated, comprehensive and multidisciplinary response. (UNODC, März 2019)


Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada.

Karamouzian M, Dohoo C, Forsting S, McNeil R, Kerr T, Lysyshyn M.

Harm Reduct J. 2018 Sep 10;15(1):46. doi: 10.1186/s12954-018-0252-8.


Assessing the 2004-2018 Fentanyl Misusing Issues Reported to an International Range of Adverse Reporting Systems.

Schifano F, Chiappini S, Corkery JM, Guirguis A.

Front Pharmacol. 2019 Feb 1;10:46. doi: 10.3389/fphar.2019.00046. eCollection 2019.


Fentanyl Family at the Mu-Opioid Receptor: Uniform Assessment of Binding and Computational Analysis.

Lipiński PFJ, Kosson P, Matalińska J, Roszkowski P, Czarnocki Z, Jarończyk M, Misicka A, Dobrowolski JC, Sadlej J.

Molecules. 2019 Feb 19;24(4). pii: E740. doi: 10.3390/molecules24040740.


Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products.

Rollman JE, Heyward J, Olson L, Lurie P, Sharfstein J, Alexander GC. 

JAMA. 2019;321(7):676–685. doi:10.1001/jama.2019.0235



Wie sich Opioide auf die Verkehrstüchtigkeit auswirken

(...) Das Team um Dr. Maren Cecilie Strand von der Abteilung für forensische Wissenschaften der Universitätsklinik Oslo nahm 22 gesunde Freiwillige in eine prospektive Studie auf und ließ sie Methadon (5 bzw. 10 mg), Buprenorphin (0,2 bzw. 0,4 mg sublingual) oder ein Placebo einnehmen. (Medical Tribune, 17.02.2019)


Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment.

Kosten TR, Baxter LE.

Am J Addict. 2019 Jan 31. doi: 10.1111/ajad.12862. [Epub ahead of print] Review.


Blockade of the human ether a-go-go related gene (hERG) potassium channel by fentanyl.

Tschirhart JN, Li W, Guo J, Zhang S.

Mol Pharmacol. 2019 Jan 21. pii: mol.118.114751. doi: 10.1124/mol.118.114751. 


Non-Medical Use of Novel Synthetic Opioids: A New Challenge to Public Health.

Lovrecic B, Lovrecic M, Gabrovec B, Carli M, Pacini M, Maremmani AGI, Maremmani I.

Int J Environ Res Public Health. 2019 Jan 9;16(2). pii: E177. doi: 10.3390/ijerph16020177. Review.


Opioide: Keine Wirkung ohne Nebenwirkung

Pharmakologen des Universitätsklinikums Jena konnten durch genetische Veränderungen am Opioid-Rezeptor in Mäusen die Entwicklung einer Toleranz gegen Opioide fast komplett unterdrücken. Die schmerzmindernde Wirkung verbesserte sich sogar und hielt auch bei längerer Gabe an, Nebenwirkungen wie Atemdepression und Obstipation sowie Abhängigkeits- und Entzugssymptome blieben jedoch unverändert. Die jetzt in Nature Communications veröffentlichte Studie legt nahe, dass die Toleranzentwicklung von Opioiden über Phosphorylierung und Desensitisierung des Opioid-Rezeptors vermittelt wird. Diese Erkenntnisse können zur Entwicklung verbesserter Opioide genutzt werden. (Universitätsklinikum Jena, 21.01.2019)


Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. 

Kliewer A, et al. 

Nat. Comm. 2019, DOI: 10.1038/s41467-018-08162-1